Answers are grounded in this paper and cite their sources.
BACKGROUND Helicobacter pylori (H. pylori ) infection remains a major etiological factor in chronic gastritis, peptic ulcer disease, and gastric cancer. The increasing prevalence of antibiotic resistance underscores the urgent need for alternative anti-H. pylori agents with clearly characterised molecular targets. AIM To investigate whether deoxyshikonin inhibits H. pylori adhesion by modulating urease-associated pathways. METHODS Anti-adhesion activity of deoxyshikonin was evaluated in GES-1 and BGC823 cells using Gram staining, fluorescence microscopy, the Alamar Blue Assay, and colony counting. Potential targets were identified using drug affinity-responsive target stability-mass spectrometry and molecular docking. Urease involvement was investigated using reverse transcription-quantitative polymerase chain reaction, western blotting, surface plasmon resonance, phenol red colorimetry, and urease activity assays. A low-urease-expression 26695Δcfa mutant and exogenous urease supplementation were applied for mechanistic validation. RESULTS Deoxyshikonin reduced cell-associated H. pylori in a concentration-dependent manner. Molecular docking suggested a stronger binding of deoxyshikonin to UreB than to UreA (-6.1 kcal/mol vs -4.9 kcal/mol). Deoxyshikonin downregulated ureA /ureB and SabA /BabA transcripts; reduced UreB protein abundance; inhibited urease activity; and directly bound to UreB , as demonstrated by surface plasmon resonance analysis (KD = 1.193 μM). The H. pylori 26695Δcfa mutant was less susceptible to deoxyshikonin, whereas exogenous urease promoted bacterial adhesion. CONCLUSION Deoxyshikonin inhibits H. pylori adhesion. The current evidence indicates that the urease subunits UreA and UreB are involved as molecular targets in this effect.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: